NCT05821153View on ClinicalTrials.gov

Low Dose IL2 Immunotherapy in AD

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

April 27, 2022

Study Completion Date

April 27, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

Aldesleukin

Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells

Trial Locations (1)

77030

Alireza Faridar, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER

NCT05821153 - Low Dose IL2 Immunotherapy in AD | Biotech Hunter | Biotech Hunter